Drugs / CD19/BCMA CAR NK
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07298590 | Dec 2025 → Jun 2028 expected | immunoglobulin G4-related sclerosing disease | Changhai Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR NK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07298590 ↗ |
| Known as | KN5601 | “CD19/BCMA CAR-NK (KN5601)” NCT07298590 ↗ |
| Modality | Cell therapy | “CD19/BCMA CAR NK cells” NCT07298590 ↗ |